Figure 6From: Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China Cost-effectiveness acceptability curve for rescue therapies for LAM-resistant HBeAg-positive (A) and HBeAg-negative (B) chronic hepatitis B. The y-axis indicates the probability that a therapy is cost-effective across willingness to pay per QALY gained (x-axis). The bold vertical two-dash and solid lines represent the thresholds for China and Shanghai City, respectively. Combination strategy uses LAM and ADV.Back to article page